{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-036388","form_type":"8-K/A","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.337496+00:00","generated_at":"2026-06-10T04:18:52.710146+00:00","sec_items":["1.01","5.02","2.01","5.06","9.01","3.02","3.01","3.03","5.03","5.01","5.05","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Conduit Pharmaceuticals completes business combination with Murphy Canyon Acquisition Corp.","bullets":["Business Combination closed on Sept 22, 2023; MURF renamed to Conduit Pharmaceuticals Inc.","65M shares of common stock issued as merger consideration to Old Conduit holders.","PIPE Financing of $20M from Nirland Limited for 2M units at $10/unit.","Approximately 2.13M public shares redeemed at ~$10.84 per share from trust.","Andrew Regan beneficially owns 62.9% of outstanding shares post-combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-036388","json":"https://secwatch.observer/filing/0001493152-23-036388.json","markdown":"https://secwatch.observer/filing/0001493152-23-036388.md","text":"https://secwatch.observer/filing/0001493152-23-036388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:18:52.710146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a93b13603","claim":"Faith L. Charles was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"118ce1d72f","claim":"Freda Lewis-Hall was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"53d7c556fc","claim":"David Tapolczay was appointed as Chief Executive Officer at CDT Equity Inc..","evidence_excerpt":"Effective upon the completion of the Business Combination, Mr. Tapolczay was appointed Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5e059f63b4","claim":"Jennifer I. McNealey was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"886d88c25a","claim":"James Bligh was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a7aba3b3e2","claim":"Freda Lewis-Hall was appointed as Chair of the Board at CDT Equity Inc..","evidence_excerpt":"Ms. Lewis-Hall was appointed as Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"e7a25334c4","claim":"Andrew Regan was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fe992415a5","claim":"David Tapolczay was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0ca393bad62992e40092acb2cb938cfab068e97e","claim":"CDT Equity Inc.: Company ceased to be a shell company as a result of the business combination.","evidence_excerpt":"As a result of the Business Combination, the Company ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"1080cae12c7a536a4fc1bf08823f46d4e18111ed","claim":"CDT Equity Inc.: Adopted amended and restated bylaws.","evidence_excerpt":"the Company adopted amended restated bylaws pursuant to an Amended and Restated Bylaws (the “A&R Bylaws”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"8004a08b5b4018500591c6e6cec654ac0b75a2a1","claim":"CDT Equity Inc.: Amended and restated certificate of incorporation in connection with business combination.","evidence_excerpt":"In connection with the completion of the Business Combination, the Company amended and restated its certificate of incorporation, effective as of the Closing Date, pursuant to the Second A&R Certificate of Incorporation","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"afbede86239def1529d73dca218fa7940c6be557","claim":"CDT Equity Inc.: Adopted a new code of conduct effective upon Closing Date.","evidence_excerpt":"Effective upon the Closing Date, in connection with the completion of the Business Combination, the Board adopted a new code of conduct","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"ce601da3d378f5208a1ffbb4504bf17f2bf6f344","claim":"CDT Equity Inc. underwent a change of control involving Conduit Pharmaceuticals Limited (Old Conduit) (closed 2023-09-22).","evidence_excerpt":"On September 22, 2023 (the \"Closing Date\"), the parties completed the Business Combination.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223036388/0001493152-23-036388-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Conduit Pharmaceuticals Limited (Old Conduit)"},{"label":"Closing","value":"2023-09-22"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}